Lilly’s obesity pill Foundayo slightly misses Q2 forecasts as injectables Mounjaro and Zepbound surge
Eli Lilly's newly launched obesity pill, Foundayo, generated $98 million in sales in Q2 2026, slightly below the consensus estimate of about $103 million, marking a modest disappointment among analysts.
Foundayo's debut quarter fell short of expectations even as Lilly's injectable GLP-1 drugs Mounjaro and Zepbound posted stellar growth, with Mounjaro revenue up 91% to $9.94 billion and Zepbound at $4.93 billion, collectively driving 64.7% of Lilly's total revenue.
The strong injectable performance underscores ongoing boom in GLP-1 obesity and diabetes therapies, while oral competitors like Novo Nordisk's Wegovy pill also underperformed expectations in the quarter, highlighting a competitive but challenging environment for obesity pills.
Sources:
Eli Lilly (LLY) earnings Q2 2026
Lilly’s Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
Eli Lilly jumps after Q2 beat driven by obesity drugs
Lilly climbs, Novo falls as obesity drug battle intensifies
Lilly's revenue soars 48%, driven by demand for its GLP-1s
Document 2 - file: q225lillysalesandearningsp.htm - SEC.gov
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss (4)
Lilly Q2 2026 Earnings: Mounjaro and Zepbound Drive 48 ...
Eli Lilly Q2 2026 earnings beat, raises full-year revenue ...
GLP-1 Q2 earnings reinforce Lilly's lead over Novo
Eli Lilly Delivers Operational Excellence, but Clinical Miss ...
Impressive growth of Eli Lilly's obesity business is coming from all over the world